X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PANACEA BIOTECH ALEMBIC PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 22.8 24.0 95.0% View Chart
P/BV x 6.0 3.2 185.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ALEMBIC PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
ALEMBIC PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs792149 532.4%   
Low Rs44382 538.3%   
Sales per share (Unadj.) Rs167.084.1 198.5%  
Earnings per share (Unadj.) Rs38.2-18.3 -208.5%  
Cash flow per share (Unadj.) Rs42.0-6.7 -626.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.983.7 101.4%  
Shares outstanding (eoy) m188.5261.25 307.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.4 269.3%   
Avg P/E ratio x16.2-6.3 -256.4%  
P/CF ratio (eoy) x14.7-17.2 -85.3%  
Price / Book Value ratio x7.31.4 527.0%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3837,074 1,645.1%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m4,2141,449 290.8%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m31,4875,154 611.0%  
Other income Rs m55100 55.2%   
Total revenues Rs m31,5425,254 600.4%   
Gross profit Rs m10,060-766 -1,312.8%  
Depreciation Rs m722711 101.6%   
Interest Rs m371,503 2.4%   
Profit before tax Rs m9,356-2,881 -324.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-2-6 26.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m2,16017 12,858.3%   
Profit after tax Rs m7,194-1,121 -641.6%  
Gross profit margin %31.9-14.9 -214.9%  
Effective tax rate %23.1-0.6 -3,958.8%   
Net profit margin %22.8-21.8 -105.0%  
BALANCE SHEET DATA
Current assets Rs m15,0663,810 395.4%   
Current liabilities Rs m7,6748,365 91.7%   
Net working cap to sales %23.5-88.4 -26.6%  
Current ratio x2.00.5 431.0%  
Inventory Days Days67156 43.0%  
Debtors Days Days4167 60.4%  
Net fixed assets Rs m8,23714,480 56.9%   
Share capital Rs m37761 615.0%   
"Free" reserves Rs m15,416903 1,707.1%   
Net worth Rs m16,0055,127 312.2%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m24,59419,433 126.6%  
Interest coverage x255.2-0.9 -27,849.3%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.30.3 482.8%   
Return on assets %29.42.0 1,496.9%  
Return on equity %44.9-21.9 -205.5%  
Return on capital %58.73.6 1,613.6%  
Exports to sales %55.724.5 227.3%   
Imports to sales %10.410.2 102.4%   
Exports (fob) Rs m17,5511,264 1,388.7%   
Imports (cif) Rs m3,283525 625.6%   
Fx inflow Rs m17,8111,539 1,157.1%   
Fx outflow Rs m5,318942 564.5%   
Net fx Rs m12,493597 2,091.8%   
CASH FLOW
From Operations Rs m9,304599 1,552.7%  
From Investments Rs m-3,105-438 709.0%  
From Financial Activity Rs m-1,959-303 647.4%  
Net Cashflow Rs m4,240-141 -3,000.7%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.6 483.3%  
FIIs % 9.1 1.3 700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.6 58.9%  
Shareholders   49,328 10,259 480.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jun 19, 2018 10:33 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS